AbbVie Inc. Long-Term Investments Change (Net)

Long-Term Investments Change (Net) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-Term Investments Change (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Long-Term Investments Change (Net) for the quarter ending December 30, 2019 was $40 Million (a -97.45% decrease compared to previous quarter)
  • Year-over-year quarterly Long-Term Investments Change (Net) decreased by -90.0%
  • Annual Long-Term Investments Change (Net) for 2019 was $2.12 Billion (a 475.0% increase from previous year)
  • Annual Long-Term Investments Change (Net) for 2018 was $368 Million (a -34.64% decrease from previous year)
  • Annual Long-Term Investments Change (Net) for 2017 was $563 Million (a -119.05% decrease from previous year)
  • Twelve month Long-Term Investments Change (Net) ending December 30, 2019 was $2.12 Billion (a 0.24% increase compared to previous quarter)
  • Twelve month trailing Long-Term Investments Change (Net) increased by 192.27% year-over-year
Trailing Long-Term Investments Change (Net) for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$2.12 Billion $2.11 Billion $2 Million $724 Million
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-Term Investments Change (Net) of AbbVie Inc.

Most recent Long-Term Investments Change (Net)of ABBV including historical data for past 10 years.

Interactive Chart of Long-Term Investments Change (Net) of AbbVie Inc.

AbbVie Inc. Long-Term Investments Change (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $40.0 $1,568.0 $108.0 $400.0 $2,116.0
2018 $35.0 $-541.0 $830.0 $44.0 $368.0
2017 $511.0 $97.0 $481.0 $-526.0 $563.0
2016 $-15.0 $-24.0 $-1,608.0 $-1,309.0 $-2,956.0
2015 $18.0 $872.0 $-850.0 $8.0 $48.0
2014 $17.0 $1,151.0 $-200.0 $-660.0 $308.0
2013 $321.0 $-607.0 $486.0 $1,575.0 $1,775.0
2012 $-202.0 $-1,825.0 $1.0 $629.0 $-1,397.0
2011 $614.44 $622.27 $-1,936.86 $12.15 $-688.0
2010 $-92.0
2009 $-4.21

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.